The Case For Including Dynamic Drug Pricing In Cost-Effectiveness Analyses Under The IRA

AUTHORS

Melanie D. Whittington, Peter J. Neumann, Joshua T. Cohen, Jonathan D. Campbell

Overview

In this publication, NPC's Chief Science Officer Jon Campbell, MS, PhD, and research colleagues from the Center for the Evaluation of Value and Risk in Health at Tufts Medical Center, argue that practitioners of cost-effectiveness analyses should incorporate dynamic drug pricing into formal cost-effectiveness analyses (CEAs). They discuss why doing so will more accurately reflect drug costs over time and how the provisions of the Inflation Reduction Act make the inclusion of dynamic drug pricing in CEAs even more important. They offer two key recommendations for practitioners of cost-effectiveness analyses.